HighTower Advisors LLC Has $294,000 Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

HighTower Advisors LLC raised its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 19.6% during the third quarter, HoldingsChannel.com reports. The fund owned 12,526 shares of the biopharmaceutical company’s stock after buying an additional 2,053 shares during the quarter. HighTower Advisors LLC’s holdings in TG Therapeutics were worth $294,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. NBC Securities Inc. boosted its position in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in TG Therapeutics in the second quarter valued at approximately $35,000. Blue Trust Inc. boosted its holdings in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 849 shares in the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth approximately $53,000. Finally, Values First Advisors Inc. bought a new stake in shares of TG Therapeutics in the 3rd quarter valued at $58,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at TG Therapeutics

In related news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

TGTX has been the topic of several research analyst reports. TD Cowen started coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock. The Goldman Sachs Group raised their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright upped their price target on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. raised their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Finally, StockNews.com lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock opened at $32.26 on Tuesday. The business has a 50 day moving average price of $29.62 and a 200-day moving average price of $24.01. TG Therapeutics, Inc. has a 52 week low of $12.84 and a 52 week high of $36.84. The company has a market cap of $5.02 billion, a PE ratio of -322.57 and a beta of 2.25. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business’s revenue was down 49.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.73 earnings per share. Equities analysts anticipate that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.